We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Kiniksa Pharmaceuticals, Ltd. (KNSA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Kiniksa Pharmaceuticals, Ltd. is one of 1003 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Kiniksa Pharmaceuticals, Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for KNSA's full-year earnings has moved 182.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that KNSA has returned about 2.5% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7%. This means that Kiniksa Pharmaceuticals, Ltd. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Krystal Biotech, Inc. (KRYS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6%.
For Krystal Biotech, Inc. the consensus EPS estimate for the current year has increased 19.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Kiniksa Pharmaceuticals, Ltd. is a member of the Medical - Biomedical and Genetics industry, which includes 509 individual companies and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have lost about 8.9% so far this year, so KNSA is performing better this group in terms of year-to-date returns. Krystal Biotech, Inc. is also part of the same industry.
Kiniksa Pharmaceuticals, Ltd. and Krystal Biotech, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Kiniksa Pharmaceuticals, Ltd. (KNSA - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Kiniksa Pharmaceuticals, Ltd. is one of 1003 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Kiniksa Pharmaceuticals, Ltd. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for KNSA's full-year earnings has moved 182.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that KNSA has returned about 2.5% since the start of the calendar year. At the same time, Medical stocks have lost an average of 7%. This means that Kiniksa Pharmaceuticals, Ltd. is outperforming the sector as a whole this year.
Another stock in the Medical sector, Krystal Biotech, Inc. (KRYS - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 6%.
For Krystal Biotech, Inc. the consensus EPS estimate for the current year has increased 19.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Kiniksa Pharmaceuticals, Ltd. is a member of the Medical - Biomedical and Genetics industry, which includes 509 individual companies and currently sits at #85 in the Zacks Industry Rank. Stocks in this group have lost about 8.9% so far this year, so KNSA is performing better this group in terms of year-to-date returns. Krystal Biotech, Inc. is also part of the same industry.
Kiniksa Pharmaceuticals, Ltd. and Krystal Biotech, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.